伴t(8;21)的急性髓系白血病近期疗效分析

目的研究影响伴t（8；21）急性髓系白血病（AML）近期疗效的因素。方法将可评判疗效的70例伴t（8；21）AML患者根据诱导治疗的疗效分为二组，A组为标准诱导治疗1—2疗程后CR患者和加用中剂量阿糖胞苷（Ara—C）方案治疗后CR患者；B组为经上述治疗后NR患者。对比二组患者性别、年龄、血象、骨髓象、染色体的差异，寻找影响近期疗效的因素。结果B组患者起病时外周血原始细胞比例、骨髓中原始细胞比例明显较A组高（P〈0．05），而骨髓中异常中幼粒的比例B组却低于A组（P〈0.05）。3例给予了中剂量Ara-C方案诱导治疗的患者，均取得了缓解。结论伴t（8；21）的AML患者起病时外周血及骨髓中原始细胞比例越高，诱导治疗缓解率越低；而骨髓中异常中幼粒比例越高，诱导治疗缓解率也越高。中剂量Ara—C方案可能会提高伴t（8；21）的AML患者诱导缓解率。

Analysis of the recent curative effect on acute myeloid leukemia with t(8;21)

Objective To study the factors that affect the recent curative effect on AML with t(8;21). Methods Divide 70 AML cases with t(8;21) into A and B group, they are all treated with typical induction regiment added middle dosage Ara- C for one or two treatment periods, the group A are CR patients, the group B are NR patients. Compare their sex, age, hemogram, bone marrow and chromsome, we want to find the factors that affect the recent curative effect. Results The patients in B group have higher level of hematopoietic stem cells in peripheral blood and bone marrow (P <0.05), while the level of abnormal myelocytes is lower (P <0.05). The three patients who received middle dosage Ara- C all got remission. Conclusion The higher level of hematopoietic stem cell in AML with t(8;21) patients' peripheral blood and bone marrow, the lower the CR rate is; the higher level of abnormal myelocyte in the bone marrow, the higher the CR rate is. And the middle dosage Ara- C regimens possibly can increase the CR rate in AML with t(8;21) patients.